PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Org Chem. Author manuscript; available in PMC 2010 November 6.
Published in final edited form as:
PMCID: PMC2783554
NIHMSID: NIHMS151476

Synthesis of a Cyclic Pentapeptide Mimic of the Active Site His-Tyr Cofactor of Cytochrome c Oxidase

Abstract

An external file that holds a picture, illustration, etc.
Object name is nihms-151476-f0001.jpg

Arylboronic acid-based technology provides a mild, regioselective and non-toxic N-arylation procedure for accessing the unusual N-arylated side chain histidine found in the active site of cytochrome c oxidase (CcO). The N-arylated histidine is elaborated to the complete cytochrome c oxidase cyclic pentapeptide cofactor. Molecular modeling of the cofactor provides insight into the dynamic character of the N-aryl bond.

Introduction

Cytochrome c oxidase (CcO) is the terminal electron acceptor of the mitochondrial electron transport chain and is responsible for the four-electron reduction of dioxygen to water.1 This reaction drives the translocation of four protons across the inner mitochondrial membrane, establishing an electrochemical gradient that drives ATP synthesis.2 The active site of CcO consists of a binuclear center (heme a3 and CuB) and a peptide cofactor, the latter of which is of particular interest to our research program. This cofactor was discovered and characterized through X-ray crystallography, revealing an unusual post-translational modification: an N-arylation linking N1 of the His240 side chain to the εC of Tyr244 (bovine heart numbering).3 The macrocyclic pentapeptide, formed with the intervening residues Pro, Glu and Val, is part of an α-helix that, along with distal His residues 290 and 291, is bound to CuB, providing a rigid binding site for the metal (Figure 1).4 A detailed understanding of this unusual cross-linkage is necessary to fully define the reaction mechanism of CcO.

Figure 1
Left – CuB of CcO Bound to the Peptide Cofactor; Right – Previously Synthesized Cofactor Mimics.

Of the four electrons needed in the catalytic cycle, it is accepted that two electrons arise from the redox cycle of heme a3 (FeII to FeIV) and one electron from the oxidation of CuB. It has been postulated that the His-Tyr crosslink plays a role in stabilizing either a Tyr radical or tyrosinate, allowing the cofactor to provide a proton5,6,7 and the fourth electron8 required to cleave the dioxygen bond and produce water. Furthermore, the His-Tyr cross-link appears to create a kink in the α-helix, placing the phenol directly at the edge of the K-channel and, thus, facilitating proton delivery to the active site.9

Previously, this laboratory synthesized models of the CcO active site incorporating a His-phenol crosslink and a pyridyl appendage that, together with the histidine main chain nitrogen, act as substitutes for the distal histidine ligands to CuB (Figure 1).10 However, these His-phenol mimics could not be expected to properly portray the effects, both electronic and structural, of the entire cyclic pentapeptide found in the native enzyme.

Electron delocalization of a tyrosine-based radical species onto the histidine imidazole through the unique C-N bond of the cofactor could be attenuated by the dihedral angle between the two aryl rings which, in turn, would be dictated by the energetics of the cyclic pentapeptide structure. In addition, the stereochemistry imparted by the biaryl dihedral angle is important for mimicking through-space interactions between the tyrosine-phenol and CuB. Thus, it seemed prudent to expand our synthetic efforts toward a cyclic pentapeptide structure that incorporates the cofactor.

Herein is presented the synthesis of macrocyclic pentapeptide 1 (Scheme 1). The native Glu has been replaced by Ala for reasons that will be discussed, and the C-terminal functionality has been removed. Hence, this model system incorporates a tyramine unit (abbreviated “tyr” to contrast with the standard 3-letter abbreviation “Tyr” for the amino acid tyrosine). Macrolactamization was executed at the His – Pro bond, utilizing the turn-inducing preference of proline to facilitate cyclization. The linear pentapeptide was assembled via coupling of the C-terminus of tripeptide A to the terminal amino group on N-arylated histidine fragment B.

Scheme 1
Retrosynthesis for the CcO Cyclic Pentapeptide Model.

Results and Discussion

Although there are many methods in the literature for N-arylation, nearly all involve the use of base and heat, conditions that are expected to be unacceptable for peptide substrates. Of the remaining methods, the substrate scope rarely incorporates substituted imidazoles, which consistently afford diminished yields due to regioselectivity issues. This laboratory previously described the regioselective N-arylation of histidine with activated tyrosine and phenol substrates using aryllead(IV) tricarboxylates under mild conditions.10 We envisioned expanding this methodology to include the His-Tyr and His-tyr systems needed to complete the synthesis of the fully formed cyclic pentapeptide mimic of CcO.

Commercially available Boc-Tyr-OH was mono-iodinated, benzyl protected (2) and protected on the phenol functionality to afford compound (3) (Scheme 2) by procedures developed in our laboratory for another project.11 Treatment with PdCl2(PPh3)2 and hexabutylditin under mild conditions provided stannylated compound (4). Transmetallation to the aryllead(IV) tricarboxylate (5) was accomplished under mercury catalysis at 30 °C. This material is highly light sensitive and must be handled under inert atmosphere; it is stable in the dark at 0 °C for several months.

Scheme 2
Synthesis of Tyrosine Aryllead(IV) triacetate.

With the suitably protected and activated tyrosine derivative prepared, N-arylations with the histidine coupling partner were examined. As with previous models, we chose to employ a histidine residue bearing both N-methyl and N-protection groups on the main chain nitrogen. Previous work had identified a facile route to Bn-MeHis-OMe and Me-His-OMe (Scheme 3).12 The former compound easily suffered ester exchange to afford allyl ester 6, while the latter compound proved to be an adequate starting material for bis-carbamate protected compound 7 and main chain carbamate protected 8.

Scheme 3
Synthesis of a suitably protected histidine coupling partner.

The first attempts at forming the desired His-Tyr coupled product followed our previously successful route in forming His-phenol model systems; namely, subjecting Bn-MeHis-OMe and aryllead(IV) reagent 5 to Cu(OAc)2 catalysis. Unfortunately, unacceptably low yields of desired product 9 were obtained by this route, with the main byproduct being the loss of lead from the tyrosine residue (Scheme 4).

Scheme 4
N-Arylation with Tyrosine Aryllead(IV) triacetate.

Additionally, simple base (LiOH) hydrolysis of methyl ester 9 surprisingly was accompanied by a more rapid (5 min at 0 °C) benzyl ester hydrolysis, leading to an inseparable mixture of the benzyl-deprotected N-arylated histidine and N-arylated histidine diacid. Consequently, non-hydrolytic methods for affecting the selective cleavage of a methyl ester in the presence of a benzyl ester were attempted. Reaction of the N-arylated histidine with Na2S (3.0 equiv) in DMPU, with or without Ti(i-OPr)4, left only unreacted substrate after 24 h. Hydrolysis attempts with the highly nucleophilic TMSOK in either Et2O or DCM were unsuccessful. One possible way to avoid this selective deprotection problem involved changing the methyl ester protection to an allyl protection on the histidine. However, the reaction of allyl ester 6 with 5 under Cu(OAc)2 catalysis also gave low yields of desired product 10. Allyl deprotection conditions using the standard palladium method adventitiously removed the N-terminal Boc group of 10. Under the more exotic ruthenium conditions, the biaryl system of 10 underwent degradation.13 It has recently been shown that ruthenium can insert into N-aryl bonds, which supports this degradation pathway.14

To explain the low arylation yields we postulated that the metal binding ability of the histidine residue, bearing both the strongly chelating imidazole ring and the main chain alkylamine in Bn-MeHis-OMe, sequestered the reactive lead species. Alternatively, this highly active metal binding site could bind spent Pb(OAc)2, thus decreasing the nucleophilic character of the imidazole and making it an unsuitable substrate for reaction with the aryllead(IV) triacetate. Thus, we looked to decrease the metal binding ability of this residue by switching the benzyl protection for the electron withdrawing –Cbz protection group and compound 8 (Scheme 4).15 In addition, we chose to eliminate the C-terminus of tyrosine, which would bypass the ester differentiation problems and, it was hoped, improve the N-arylation yields (Table 1). To this end, aryllead(IV) tyramine derivative 14, comparable to tyrosine derivative 5 was prepared (Scheme 5).

Scheme 5
Synthesis of Tyramine Aryllead(IV) tricarboxylate.
Table 1
Optimizing the N-arylation.

Commercially available tyramine·HCl was nitrogen protected and iodinated to give 11 under the conditions developed for the synthesis of 3, then subjected to phenol protection under standard conditions to give 12.16 Stannylation (13) and subsequent plumbation yielded aryllead(IV) coupling partner 14 (Scheme 5).

Although the tyramine aryllead(IV) triacetate could be prepared in improved yield over the tyrosine system, the N-arylation yields were uniformly low (Table 1, entries 1-4). Variations in copper source and the addition of DBU, which has been used to increase yields in certain aryllead coupling reactions,17 did not lead to increased recovery of desired product. Therefore, more traditional methods for N-arylation, employing aryl iodides, were explored; however, no product was observed for any of these reactions (entries 5, 6).18

Lam-Chan coupling procedures have been used for the arylation of simple imidazoles with arylboronic acids.19 However, such protocols require the use of two equivalents of boronic acid and struggle with regioselectivity issues on substituted imidazole substrates. Nonetheless, we next attempted to produce a tyramine coupling partner functionalized with a boronic acid group.

A variety of methods were screened to affect the Miyaura reaction on iodide 12, including both microwave and conventional heating as well as variations in ligand design.20,21,22 Optimal conditions included the use of pinacol borane rather than the traditional bis-pinacol borane and DCBP as a ligand to afford crystalline aryl boronic ester 17 (Scheme 6). Oxidative cleavage of the boronate ester with NaIO4 provided arylboronic acid 18 in 88% yield.

Scheme 6
Synthesis of Tyramine Boronic Ester, Acid and Trifluoroborate

Unfortunately, Lam-Chan type coupling with CuI in MeOH provided no product (Table 1, entry 7). A procedure by Collman et al. for the N-arylation of imidazoles with arylboronic acids, originally based on the work of Lam-Chan, was adopted for our needs.23 Collman reported high yields and mild conditions using a catalytic amount of a novel copper system (in the form [Cu(OH)TMEDA]2Cl2) under aerobic conditions, albeit with modest regioselectivity for substituted imidazoles. Additionally, as in the aryllead case, a 40% excess of arylboronic acid is needed with respect to the imidazole. However, in our hands the optimal reaction conditions afforded 61% of the N-arylated histidine 16 (Table 1, entry 8) as a single regioisomer using a 1/1 ratio of boronic acid to histidine.24 It should be noted that this stoichiometery represents an unusual finding in that commonly a 2/1 ratio of boronic acid to histidine is optimal. The use of 4 Å molecular sieves, as employed by Collman, afforded variable yields and were, therefore, not used.

Much of the same arylboronic acid chemistry can be achieved with the easily prepared and highly crystalline trifluoroborate salts.25 Attempts to by-pass the arylboronic ester in synthesizing the trifluoroborate salt 19 from 12 failed,26 but proceeded from 17 by treatment with KHF2.27 N-arylation reactions failed with the trifluoroborate salt (Table 1, entry 9). However, 19 could be easily recrystallized and hydrolyzed to 18 for incorporation into the optimized procedure.28

With a viable His-tyr dipeptide fragment in hand (B in Scheme 1), tripeptide Boc-Pro-Ala-Val-OH 22 (serving as fragment A in Scheme 1) was prepared easily on a large scale (Scheme 7). Alanine was chosen to replace the glutamic acid residue of the mammalian CcO structure to avoid any additional problems with side chain protection groups. It was believed that this replacement would not have an impact on the ring conformation and C-N bond rotation energetics. Dipeptide 20 was prepared in high yield using an HOBt/EDC coupling of Boc-Ala-OH with H-Val-OMe·HCl,29 which was then nitrogen deprotected under standard conditions and coupled with Boc-Pro-OH to provide protected tripeptide 21. Hydrolysis revealed N-protected tripeptide 22.

Scheme 7
Synthesis of Tripeptide 2.

Selective deprotection of the N-Boc functionality of 16 in the presence of the - MOM group was performed (10% impurity of MOM deprotected material)30 prior to standard HOBt/EDCI coupling with 22, which afforded the linear pentapeptide 23 in 83% yield (Scheme 8, 58% overall for the 2 steps). Other methods, such as CIP31 or PyBOP/HOAt, resulted in significant byproduct formation.

Scheme 8
Synthesis of Cytochrome c Oxidase Peptide Cofactor 1.

Standard LiOH hydrolysis of the methyl ester in 23 was accomplished in high yield. This crude salt was subjected to TFA deprotection of the remaining -Boc group, again in the presence of the -MOM functionality, to provide the linear pentapeptide as a free carboxylic acid/ammonium salt, which was taken on without purification to the cyclization reaction. At this stage, a variety of activation agents were screened in an attempt to cyclize this 21-membered macrocycle. Among them, PyBOP/HOAt and EDC/HOBt provided only minimal product after 2 d of reaction, whereas EDC/pentafluorophenol (Pfp) provided the ring-closed intermediate at an exceptional rate. This material was fully MOM deprotected in high yield, providing the free phenol macrocyclic pentapeptide 24, as confirmed by LCMS and single crystal X-ray analysis (Figure 2). At this point, the Cbz group was removed with Parr hydrogenolysis to provide the complete pentapeptide 1, which includes the cytochrome c oxidase peptide cofactor.

Figure 2
Crystal structure of cyclic pentapeptide 24.32

Modeling

Our goal was to synthesize a compound that more closely resembled the natural peptide system in CcO as regards to the global conformation and corresponding rotational freedom around the novel C-N bond linking the two aryl side chains (biaryl dihedral angle, BDA), in full recognition of the significant contributions likely made by both metals, their corresponding ligand systems and the polypeptide structure of the native protein.

Of all the compounds studied in this laboratory, the crystal structure of compound 24 exhibits a BDA magnitude most like the native system. However, the sign is opposite (−40°, synthetic; +44°, native). It is compelling to propose that this similarity in BDA magnitude represents the natural tendency of the bicyclic system33 based on sound physical organic chemistry principles, and that the sign is dictated by second sphere forces (heme, metals, polypeptide backbone). By contrast, the dihedral angles ([var phi],ψ) defining the cyclic peptide backbone are found to be quite different from those of the native system (Table 2).

Table 2
([var phi]ψ) Angles of Native and Synthetic Peptide.

The barrier to rotation around the unusual C-N bond was probed through computational studies.34 Driving the dihedral from −40° to +40° over 10° increments and minimizing the energy at each step provided the ensemble of structures shown in Figure 3. The barrier to rotation about this bond was 12.6 kcal/mol, low enough so that in solution there is no expectation of atropisomer formation. The dynamic nature of this biaryl system has a two-fold impact. First, the lack of atropisomers simplifies the purification process of the complete cyclic pentapeptide. Second, it has been proposed that the conformational changes between the oxidized and reduced forms of the enzyme are implicated in proton pumping.35 A flexible biaryl system is required for this conformational mobility.

Figure 3
Ensemble of structures minimized about the biaryl bond.

Conclusion

Synthesis of a pentapeptide containing the unusual amino acid cofactor of cytochrome c oxidase has been presented. Key to the synthesis was an N-arylation procedure, which improved the stoichiometry and regiocontrol over previous methods. The biaryl dihedral angle is found to be almost identical in magnitude to that found in the natural system, while opposite in sign. Continued synthetic efforts to append a copper binding site to the histidine residue of the cyclic pentapeptide are ongoing and will be reported in due course.

Experimental Section

(S)-Methyl 2-((Benzyloxycarbonyl)(methyl)amino)-3-(1-(5-(2-(tert-butoxycarbonylamino)ethyl)-2-(methoxymethoxy)phenyl)-1H-imidazol-4-yl)propanoate (16)

A solution of histidine derivative 8 (0.51 g, 1.61 mmol, 1.0 equiv) in DCM (6.4 mL, 0.1 M) was added to freshly prepared boronic acid 18 (0.52 g, 1.61 mmol, 1.0 equiv). Copper catalyst [Cu(OH)TMEDA]2Cl2 (0.074 g, 0.161 mmol, 0.1 equiv) was added to the reaction under N2, which turned the solution dark blue. A drying tube (CaSO4) was put in place to allow diffusion of dry air into the reaction mixture, which turned the solution a pale aqua color. After stirring for 36 h the reaction was concentrated to a green oil and loaded onto a column for purification with 1:4 ethyl acetate/hexanes followed by ethyl acetate. 0.59 g (61%) was recovered as a clear oil. 1.0 : 0.9 dr (Cbz rotomers on main chain nitrogen); 1H NMR (500 MHz, CDCl3): δ (ppm) 7.68 (d, J = 14.0 Hz, 1H), 7.23 – 7.29 (m, 5H), 7.19 (dd, J = 1.0, 8.5 Hz, 1H), 7.13 (d, J = 8.5 Hz, 1H), 7.04 (d, J = 9.5 Hz, 1H), 6.978 (s, 1H), [6.88 (s, 1H)], 5.11 (s, 2H), 5.06 – 5.08 (m, 2H), 5.01 – 5.03 (m, 1H), [4.92 – 4.93 (m, 1H)], 4.62 (bs, 1H), 3.74 (s, 3H), [3.64 (s, 3H)], 3.33 (s, 3H), [3.32 (s, 3H)], 3.305 – 3.34 (m, 2H), 3.06 – 3.19 (m, 2H), 2.91 (s, 3H), [2.90 (s, 3H)], 2.76 (d, J = 4.0 Hz, 2H), 1.41 (s, 9H); 13C NMR (125 MHz, CDCl3): δ (ppm) 171.4, 155.7, 137.9, 136.4, 133.4, 128.9, 128.9, 128.3, 127.7, 127.4, 125.6, 116.6, 116.5, 95.1, 79.2, 67.1, 59.5, 56.2, 52.2, 52.1, 41.5, 35.1, 28.2; HRMS for C31H41N4O8 [M+H] calcd., 597.2919, found, 597.3001 (Error = 13.73 ppm); [α]D28 (c 0.2, MeOH); IR (thin film) 1642, 1519, 1404, 1344, 1145, 1039, 990 cm−1.

Cyclic Pentapeptide, N-Cbz protection·TFA salt (24)

Linear pentapeptide 23 (0.23 g, 0.26 mmol, 1.0 equiv) was dissolved in a 1/1 mixture of THF/H2O (5.2 mL, 0.05 M) and cooled to 0 °C. After the solution reached 0 °C, LiOH (0.033 g, 0.79 mmol, 3.0 equiv) was added and stirred for 1 h, at which point the ice bath was removed and the solution was allowed to reach rt where it was kept for an additional 2 h. The THF was removed in vacuo and the aqueous mixture was loaded onto a 50 mL Sephadex C18 solid phase extraction column (preconditioned by running a column volume (cv) of MeOH followed by one cv of H2O). The sample was eluted with 3 cvs of H2O followed by 3 cvs of MeOH. The sample eluted immediately with MeOH over ~ 20 mL. The organic layer contained only the desired acid salt as determined by LCMS. These fractions were lyophilized to provide the linear pentapeptide lithium carboxylate salt. This salt was dissolved in TFA (2.6 m, 0.1 M) at rt and stirred for 4 min. At this time, 100 mL of DCM was added and the solution was evaporated in vacuo. The compound was evaporated two additional times with DCM to provide the bis-TFA salt as a yellow oil. Some (10%) of this material was free phenol (-MOM), deprotected under these conditions and was carried through as a mixture. For R = MOM; HRMS for C38H50N7O8 [M+H] calcd., 732.37154, found, 732.3782 (Error = 9.09 ppm). To the oil was added DMF (6.6 mL, 0.05 M). The solution was cooled to 0 °C and EDC (0.05 g, 0.26 mmol, 1.0 equiv) and pentafluorophenol (Pfp) (0.24 g, 1.32 mmol, 5.0 equiv) in DMF (3.3 mL) were added. This mixture was allowed to react for 30 min. At this point the pH of the solution was increased with the addition of DIPEA (0.44 mL, 2.64 mmol, 10.0 equiv). The reaction was periodically monitored by LCMS, which indicated that cyclization proceeded rapidly (little starting material remained after 15 min) and was complete after 3 h. An LCMS of the crude reaction mixture revealed only the presence of product (a variable mixture of MOM protected and deprotected) with Pfp as the only other identifiable product. Purification was accomplished with a C18 Sephadex column (prepared as described previously for isolating the carboxylate salt). The reaction mixture was diluted with water (50 mL) and loaded onto the column. This was eluted with 3 cvs of H2O followed by 3 cvs of MeOH. This first separation is used to remove all DMF. After the organics were removed a second purification was necessary. The crude product was loaded with 20% MeOH/H2O and eluted in 10 mL portions of 50, 60, 70, 80, 90, 100% (20 mL) MeOH/H2O. The desired material eluted between the 80 and 90% MeOH/H2O gradient. The purity was analyzed by LCMS analysis; see chromatograph in Supporting Information Part 2. The macrocyclic pentapeptide (0.030 g, 0.036 mmol), as a variable mixture of MOM protected and MOM deprotected material, was stirred in a 1:1 TFA/DCM (1 mL) mixture. After 2 h the mixture was concentrated in vacuo and any excess TFA was removed by evaporation with DCM. X-ray quality crystals were grown from a H2O/DMSO/CH3CN solvent system, which confirmed the connectivity of compound 24. Data for R = H; Due to the multiple conformations in solution, see 1H and 13C NMR spectra for purity. HRMS for C36H46N7O7 [M+H], calcd., 688.3453, found, 688.3402 (Error = 7.41 ppm); [α]D28 (c 3.3, DMSO).

Supplementary Material

1_si_001

2_si_002

3_si_003

Acknowledgements

We wish to thank the NIH [GM53788 (Ó. E.) for partial funding of this work. Purchase of the 600 MHz NMR used in these studies was supported by funds from the National Institute of Health (S10RR019918) and National Science Foundation (CHE-0342912). Samples for synchrotron crystallographic analysis were submitted through the SCrALS (Service Crystallography at Advanced Light Source) program. Crystallographic data were collected at Beamline 11.3.1 at the Advanced Light Source (ALS), Lawrence Berkeley National Laboratory. The ALS is supported by the U.S. Dept. of Energy, Office of Energy Sciences, under contract DE-AC02-05CH11231. The authors would also like to thank C. M. Binder and R. A. Turner for their insightful conversations.

Footnotes

Supporting Information Available: Synthetic procedures, complete spectroscopic data, 1H, 11B and 13C NMR spectra for all new compounds, LCMS and CIF data for 24 are available free of charge via the Internet at http://pubs.acs.org.

References

(1) Ferguson-Miller S, Babcock GT. Chem. Rev. 1996;96:2889–2907. [PubMed]
(2) Wikström MKF. Nature (London) 1977;266:271–273. [PubMed]
(3)(a) Yoshikawa S, Shinzawa-Itoh K, Nakashima R, Yaono R, Yamashita E, Inoue N, Yao M, Fei MJ, Libeu CP, Mizushima T, Yamaguchi H, Tomizaki T, Tsukihara T. Science. 1998;280:1723–1729. [PubMed] (b) Ostermeier C, Harrenga A, Ermler U, Michel H. Proc. Natl. Acad. Sci. U.S.A. 1997;94:10547–10553. [PubMed] (c) Soulimane T, Buse G, Bourenkov GP, Bartunik HD, Huber R, Than ME. EMBO J. 2000;19:1766–1776. [PubMed]
(4) PDB ID: 2zxw. Aoyama H, Muramoto K, Shinzawa-Itoh K, Hirata K, Yamashita E, Tsukihara T, Ogura T, Yoshikawa S. Proc. Nat. Acad. Sci. U.S.A. 2009;106:2165–2169. [PubMed]
(5) Proshlyakov DA, Pressler MA, Babcock GT. Proc. Natl. Acad. Sci. U.S.A. 1998;95:8020–8025. [PubMed]
(6) Gennis RB. Biochim. Biophys. Acta. 1998;1365:241–248.
(7) Sucheta A, Szundi I, Einarsdóttir Ó. Biochemistry. 1998;37:17905–17914. [PubMed]
(8)(a) Blomberg MRA, Siegbahn PEM, Babcock GT, Wikström MKF. J. Inorg. Biochem. 2000;80:261–269. [PubMed] (b) Svistunenko DA, Wilson MT, Cooper CE. Biochim. Biophys. Acta. 2004;1655:372–380. [PubMed] (c) Proshlyakov DA, Pressler MA, DeMaso C, Leykam JF, Dewitt DL, Babcock GT. Science. 2000;290:1588–1591. [PubMed] (d) Tomson F, Bailey JA, Gennis RB, Unkefer CJ, Li ZH, Silks LA, Martinez RA, Donohoe RJ, Dyer RB, Woodruff WH. Biochemistry. 2002;41:14383–14390. [PubMed] (e) Nyquist RM, Heitbrink D, Bolwien C, Gennis RB, Heberle J. Proc. Natl. Acad. Sci. U.S.A. 2003;100:8715–8720. [PubMed]
(9) Proshlyakov DA, Pressler MA, Babcock GT. Proc. Natl Acad. Sci. U.S.A. 1998:8020–8025. [PubMed]
(10)(a) Elliott GI, Konopelski JP. Org. Lett. 2000;2:3055–3057. [PubMed] (b) Cappuccio JA, Ayala I, Elliott GI, Szundi I, Lewis J, Konopelski JP, Barry BA, Einarsdóttir Ó. J. Am. Chem. Soc. 2002;124:1750–60. [PubMed] (c) Landaverry YR, White KN, Olmstead MM, Einarsdóttir Ó, Konopelski JP. Heterocycles. 2006;70:147–152. (d) White KN, Sen I, Szundi I, Landaverry YR, Bria LE, Konopelski JP, Olmstead MM, Einarsdóttir Ó. Chem. Commun. 2007;31:3252–3254. [PubMed]
(11) Moore EM. Masters Thesis. University of California Santa Cruz; 2000.
(12) White KN, Konopelski JP. Org. Lett. 2005;7:4111–4112. [PubMed]
(13) Kawasaki T, Enoki H, Matsumura K, Ohyama M, Inagawa M, Sakamoto M. Org. Lett. 2000;2:3027–3029. [PubMed]
(14) Koreeda T, Kochi T, Kakiuchi F. J. Am. Chem. Soc. 2009;131:7238–7239. [PubMed]
(15) Shieh W–C, Xue S, McKenna J, Prasad K, Repič O, Blacklock T. Tetrahedron Lett. 2006;47:5645–5648.
(16) Hart ME, Suchland KL, Miyakawa M, Bunzow JR, Grandy DK, Scanlan TS. J. Med. Chem. 2006;49:1101–1112. [PubMed]
(17) Pinhey JT, Rowe BA. Aust. J. Chem. 1983;36:789–794.
(18)(a) Shafir A, Buchwald SL. J. Am. Chem. Soc. 2006;128:8742–8743. [PubMed] (b) Jiang Q, Jiang D, Jiang Y, Fu H, Zhao Y. Synlett. 2007:1836–1842. (c) Zhu L, Li G, Luo L, Guo P, Lan J, Youet J. J. Org. Chem. 2009;74:2200–2202. [PubMed]
(19)(a) Lam PYS, Clark CG, Saubern S, Adams J, Winters MP, Chan DMT, Combs A. Tetrahedron Lett. 1998;39:2941–2944. (b) Lan J–B, Chen L, Yu X–Q, You J–S, Xie R–G. Chem. Commun. 2004:188–189. [PubMed]
(20) Gerstenberger BS. Ph.D. Thesis. University of California; Santa Cruz: 2007.
(21) Poriel C, Lachia M, Wilson C, Davies JR, Moody CJ. J. Org. Chem. 2007;72:2978–2987. [PubMed]
(22) Decicco CP, Song Y, Evans DA. Org. Lett. 2001;3:1029–1032. [PubMed]
(23) Collman JP, Zhong M. Org. Lett. 2000;2:1233–1236. [PubMed]
(24) Increasing the arylboronic acid to histidine ratio to 1.4:1 does not improve the yield.
(25) Molander GA, Figueroa R. Aldrichim. Acta. 2005;38:49.
(26) Park YH, Ahn HR, Canturk B, Jeon SI, Lee S, Kang H, Molander GA, Ham J. Org. Lett. 2008;10:1215–1218. [PubMed]
(27) Skaff O, Jolliffe KA, Hutton CA. J. Org. Chem. 2005;70:7353–7363. [PubMed]
(28) Yuen AKL, Hutton CA. Tetrahedron Lett. 2005;46:7899–7903.
(29) Ginisty M, Roy M–N, Charette AB. J. Org. Chem. 2008;73:2542–2547. [PubMed]
(30) Nicolaou KC, Chen DY–K, Huang X, Ling T, Bella M, Snyder SA. J. Am. Chem. Soc. 2004;126:12888–12896. [PubMed] While this 10% impurity of free phenol was removed to obtain a pure sample of 23, its presence posed no problems for the production of 24.
(31) Akaji K, Hayashi Y, Kiso Y, Kuriyama N. J. Org. Chem. 1999;64:405–411.
(32) Solvent and water molecules omitted for clarity.
(33) DFT calculations on simple model systems (Pratt DA, Pesavento RP, van der Donk WA. Org. Lett. 2005;7:2735–2738. [PubMed] put the BDA at 42.5°, very close to the native enzyme BDA. Most x-ray structures, including our own previous work, suffer from intermolecular hydrogen bonds that likely perturb the fundamental BDA; in our laboratory we have documented BDAs ranging from −25.7° to −36.3°. By contrast, the structure of 24 appears devoid of serious intermolecular interactions. Hence, this molecule affords the best experimental evidence for the intrinsic BDA of the biaryl cofactor.
(34) Macromodel v9.0.014 was used for the calculations. The Amber* force field was employed, dielectric = 80, with a PRCG minimization method.
(35) Qin L, Liu J, Mills DA, Proshlyakov DA, Hiser C, Ferguson-Miller S. Biochemistry. 2009;48:5121–5130. [PMC free article] [PubMed]